Surgical endoscopy · 2026
RedoPOEM: efficacy and safety after failure of a first POEM for esophageal motility disorders.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
D'Angelo Amaury, Pioche Mathieu, Barret Maximilien, Gonzalez Jean-Michel, Wallenhorst Timothée, Coron Emmanuel, Velut Guillaume, Vanbiervliet Geoffroy, Onana Ndong Philippe, Jacques Jérémie, Schaefer Marion, Levy Jonathan, Caillo Ludovic, Rahmi Gabriel, Aidibi Ali, Ah-Soune Philippe, Degand Thibault, Saunier Maxime, Zerbib Frank, Berger Arthur
Аннотация
INTRODUCTION: Per-oral endoscopic myotomy (POEM) achieves an 80-90% success rate for the treatment of esophageal motility disorders, but approximately 10% of patients experience persistent symptoms. This study evaluated the results of a repeat POEM procedure, or redoPOEM, as a second-line therapy.
METHODS: We conducted a retrospective multicenter study involving 15 French tertiary centers, including all patients undergoing redoPOEM between April 2015 and September 2023. Short and long-term success rates were defined as an Eckardt score < 4 at 3 months, and at the last follow-up visit with no need for additional treatment, respectively. Adverse events were graded using the AGREE classification.
RESULTS: Eighty-seven patients (mean age 56.5 years, 57% male) were included; 89.7% had achalasia and 10.3% had non-achalasia motility disorders. The median pre-redoPOEM Eckardt score was 6. The average follow-up duration was 22 months. At 3 months, 78.2% achieved clinical success (median Eckardt score: 1). Long-term success was obtained in 57.1% at 1 year follow-up. Additional treatments were required in 28%. Univariate and multivariate analyses identified a high pre-redoPOEM Eckardt score and prior treatments before POEM as predictors of failure. Adverse events (grade II or higher) occurred in 11.4%, including pneumonia and mucosal breaches, but no deaths were reported.
CONCLUSION: RedoPOEM is effective and safe for managing primary failure or symptomatic recurrence after a first POEM. A high pre-redoPOEM Eckardt score and previous treatments are predictive of primary failure.
CLINICAL TRIALS NUMBER: NCT06044155.
METHODS: We conducted a retrospective multicenter study involving 15 French tertiary centers, including all patients undergoing redoPOEM between April 2015 and September 2023. Short and long-term success rates were defined as an Eckardt score < 4 at 3 months, and at the last follow-up visit with no need for additional treatment, respectively. Adverse events were graded using the AGREE classification.
RESULTS: Eighty-seven patients (mean age 56.5 years, 57% male) were included; 89.7% had achalasia and 10.3% had non-achalasia motility disorders. The median pre-redoPOEM Eckardt score was 6. The average follow-up duration was 22 months. At 3 months, 78.2% achieved clinical success (median Eckardt score: 1). Long-term success was obtained in 57.1% at 1 year follow-up. Additional treatments were required in 28%. Univariate and multivariate analyses identified a high pre-redoPOEM Eckardt score and prior treatments before POEM as predictors of failure. Adverse events (grade II or higher) occurred in 11.4%, including pneumonia and mucosal breaches, but no deaths were reported.
CONCLUSION: RedoPOEM is effective and safe for managing primary failure or symptomatic recurrence after a first POEM. A high pre-redoPOEM Eckardt score and previous treatments are predictive of primary failure.
CLINICAL TRIALS NUMBER: NCT06044155.